Optimized sigma-1 agonist method of responder selection and treatment
US12383526B2 · kind B2 · utility
0Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2019 |
| Grant date | Aug 12, 2025 |
| Priority date | — |
| Expiry date | May 24, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy. Also described is use of the polymorphisms to personalize treatment for subjects in need of Sigma-1 receptor therapy such as treatment of neurodevelopmental and neurodegenerative diseases and conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.